Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis

Detalhes bibliográficos
Autor(a) principal: Adtani, Pooja Narain
Data de Publicação: 2024
Outros Autores: Subbarayan , Rajasekaran, Shrestha , Rupendra, Elsayed , Walid
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Dental Science
Texto Completo: https://ojs.ict.unesp.br/index.php/cob/article/view/4172
Resumo: Oral Submucous Fibrosis is a potentially malignant disorder caused by habitual areca nut chewing, which contributes to the dispersion of active alkaloids into subepithelial tissues, stimulating excessive extracellular matrix deposition. Various treatment modalities are available; however, their efficacy in inhibiting fibrosis progression remains limited. Sulforaphane (SFN), an isothiocyanate found abundantly in cruciferous plants, is known to have effective antifibrotic properties. Objective: The present study investigated the antifibrotic effect of SFN via phosphatidylinositol 3 kinase (PI3K), Serine/Threonine Kinase 1 (AKT-1), mammalian target of rapamycin (mTOR) pathway in arecoline (AER) induced fibrosis in human gingival fibroblasts [HGFs]. Material and Methods: MTT assay determined the half-maximal inhibitory concentration of AER and SFN at 24h in the HGF cell line. Expression levels of transforming growth factor B1 (TGFB1), collagen type 1 alpha 2 (COL1A2), hydroxyproline (HYP), PI3, AKT, mTOR, and nuclear factor erythroid 2–related factor 2 (NRF2) were assessed post-AER and SFN treatment using qPCR and western blot analysis. Results: The findings of the study revealed that AER elicited a stimulatory effect, upregulating TGFB1, COL1A2, HYP, PI3K, AKT, and mTOR and downregulating NRF2 expression. Conversely, SFN treatment significantly upregulated NRF2, inhibiting TGFB1 mediated PI3/ AKT/mTOR pathway. Conclusion: These observations suggest that SFN can be used as a promising synergistic antifibrotic agent to combat fibrogenesis via the non-Smad pathway. KEYWORDS Arecoline; NRF2; Oral submucous fibrosis; PI3/AKT/mTOR; Sulforaphane.
id UNESP-20_84fe6f1460ed3c313a87eddfcc25ce5b
oai_identifier_str oai:ojs.pkp.sfu.ca:article/4172
network_acronym_str UNESP-20
network_name_str Brazilian Dental Science
repository_id_str
spelling Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosisOral Submucous Fibrosis is a potentially malignant disorder caused by habitual areca nut chewing, which contributes to the dispersion of active alkaloids into subepithelial tissues, stimulating excessive extracellular matrix deposition. Various treatment modalities are available; however, their efficacy in inhibiting fibrosis progression remains limited. Sulforaphane (SFN), an isothiocyanate found abundantly in cruciferous plants, is known to have effective antifibrotic properties. Objective: The present study investigated the antifibrotic effect of SFN via phosphatidylinositol 3 kinase (PI3K), Serine/Threonine Kinase 1 (AKT-1), mammalian target of rapamycin (mTOR) pathway in arecoline (AER) induced fibrosis in human gingival fibroblasts [HGFs]. Material and Methods: MTT assay determined the half-maximal inhibitory concentration of AER and SFN at 24h in the HGF cell line. Expression levels of transforming growth factor B1 (TGFB1), collagen type 1 alpha 2 (COL1A2), hydroxyproline (HYP), PI3, AKT, mTOR, and nuclear factor erythroid 2–related factor 2 (NRF2) were assessed post-AER and SFN treatment using qPCR and western blot analysis. Results: The findings of the study revealed that AER elicited a stimulatory effect, upregulating TGFB1, COL1A2, HYP, PI3K, AKT, and mTOR and downregulating NRF2 expression. Conversely, SFN treatment significantly upregulated NRF2, inhibiting TGFB1 mediated PI3/ AKT/mTOR pathway. Conclusion: These observations suggest that SFN can be used as a promising synergistic antifibrotic agent to combat fibrogenesis via the non-Smad pathway. KEYWORDS Arecoline; NRF2; Oral submucous fibrosis; PI3/AKT/mTOR; Sulforaphane.Institute of Science and Technology of São José dos Campos2024-04-17info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://ojs.ict.unesp.br/index.php/cob/article/view/417210.4322/bds.2024.e4172Brazilian Dental Science; Vol. 27 No. 1 (2024): Jan - Mar / 2024 - Published Jan 2024Brazilian Dental Science; v. 27 n. 1 (2024): Jan - Mar / 2024 - Published Jan 20242178-6011reponame:Brazilian Dental Scienceinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPenghttps://ojs.ict.unesp.br/index.php/cob/article/view/4172/4714Copyright (c) 2024 Brazilian Dental Scienceinfo:eu-repo/semantics/openAccessAdtani, Pooja NarainSubbarayan , Rajasekaran Shrestha , Rupendra Elsayed , Walid 2024-04-01T17:45:19Zoai:ojs.pkp.sfu.ca:article/4172Revistahttp://bds.ict.unesp.br/PUBhttp://ojs.fosjc.unesp.br/index.php/index/oaisergio@fosjc.unesp.br||sergio@fosjc.unesp.br2178-60112178-6011opendoar:2024-04-01T17:45:19Brazilian Dental Science - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis
title Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis
spellingShingle Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis
Adtani, Pooja Narain
title_short Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis
title_full Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis
title_fullStr Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis
title_full_unstemmed Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis
title_sort Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis
author Adtani, Pooja Narain
author_facet Adtani, Pooja Narain
Subbarayan , Rajasekaran
Shrestha , Rupendra
Elsayed , Walid
author_role author
author2 Subbarayan , Rajasekaran
Shrestha , Rupendra
Elsayed , Walid
author2_role author
author
author
dc.contributor.author.fl_str_mv Adtani, Pooja Narain
Subbarayan , Rajasekaran
Shrestha , Rupendra
Elsayed , Walid
description Oral Submucous Fibrosis is a potentially malignant disorder caused by habitual areca nut chewing, which contributes to the dispersion of active alkaloids into subepithelial tissues, stimulating excessive extracellular matrix deposition. Various treatment modalities are available; however, their efficacy in inhibiting fibrosis progression remains limited. Sulforaphane (SFN), an isothiocyanate found abundantly in cruciferous plants, is known to have effective antifibrotic properties. Objective: The present study investigated the antifibrotic effect of SFN via phosphatidylinositol 3 kinase (PI3K), Serine/Threonine Kinase 1 (AKT-1), mammalian target of rapamycin (mTOR) pathway in arecoline (AER) induced fibrosis in human gingival fibroblasts [HGFs]. Material and Methods: MTT assay determined the half-maximal inhibitory concentration of AER and SFN at 24h in the HGF cell line. Expression levels of transforming growth factor B1 (TGFB1), collagen type 1 alpha 2 (COL1A2), hydroxyproline (HYP), PI3, AKT, mTOR, and nuclear factor erythroid 2–related factor 2 (NRF2) were assessed post-AER and SFN treatment using qPCR and western blot analysis. Results: The findings of the study revealed that AER elicited a stimulatory effect, upregulating TGFB1, COL1A2, HYP, PI3K, AKT, and mTOR and downregulating NRF2 expression. Conversely, SFN treatment significantly upregulated NRF2, inhibiting TGFB1 mediated PI3/ AKT/mTOR pathway. Conclusion: These observations suggest that SFN can be used as a promising synergistic antifibrotic agent to combat fibrogenesis via the non-Smad pathway. KEYWORDS Arecoline; NRF2; Oral submucous fibrosis; PI3/AKT/mTOR; Sulforaphane.
publishDate 2024
dc.date.none.fl_str_mv 2024-04-17
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://ojs.ict.unesp.br/index.php/cob/article/view/4172
10.4322/bds.2024.e4172
url https://ojs.ict.unesp.br/index.php/cob/article/view/4172
identifier_str_mv 10.4322/bds.2024.e4172
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://ojs.ict.unesp.br/index.php/cob/article/view/4172/4714
dc.rights.driver.fl_str_mv Copyright (c) 2024 Brazilian Dental Science
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2024 Brazilian Dental Science
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Institute of Science and Technology of São José dos Campos
publisher.none.fl_str_mv Institute of Science and Technology of São José dos Campos
dc.source.none.fl_str_mv Brazilian Dental Science; Vol. 27 No. 1 (2024): Jan - Mar / 2024 - Published Jan 2024
Brazilian Dental Science; v. 27 n. 1 (2024): Jan - Mar / 2024 - Published Jan 2024
2178-6011
reponame:Brazilian Dental Science
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Brazilian Dental Science
collection Brazilian Dental Science
repository.name.fl_str_mv Brazilian Dental Science - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv sergio@fosjc.unesp.br||sergio@fosjc.unesp.br
_version_ 1800214394603307008